1. Acknowledgement to Referees

   Acknowledgement to Referees 20 November 2018 Pages: 1079 - 1083

2. Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

   • Jacoline C. Bouvy
   • Pall Jonsson
   • John Gallacher

   Current Opinion Open access 22 November 2018 Pages: 1085 - 1090

   

3. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

   • Juliane Gust
   • Agne Taraseviciute
   • Cameron J. Turtle

   Leading Article 01 November 2018 Pages: 1091 - 1101

4. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis

   • Pierre Ellul
   • Richard Delorme
   • Samuele Cortese

   Systematic Review 20 September 2018 Pages: 1103 - 1112

   

5. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms

   • Maira Aguiar Werneck
   • Guilherme Trevizan Kortas
   • João Mauricio Castaldelli-Maia

   Systematic Review 25 October 2018 Pages: 1113 - 1129

   

6. VMAT2 Inhibitors in Neuropsychiatric Disorders

   • Arjun Tarakad
   • Joohi Jimenez-Shahed

   Review Article 10 October 2018 Pages: 1131 - 1144

7. Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

   • Marita Zimmermann
   • Elizabeth Brouwer
   • Josh J. Carlson

   Original Research Article 23 August 2018 Pages: 1145 - 1157

   

8. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

   • Alexander Klistorner
   • Yi Chai
   • RENEW MF-VEP Investigators

   Original Research Article Open access 28 September 2018 Pages: 1159 - 1171

   

9. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

   • Mark Gudesblatt
   • Karl Wissemann
   • Lily Lee

   Original Research Article Open access 24 August 2018 Pages: 1173 - 1181

   

10. Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

    • Mark Gudesblatt
    • Karl Wissemann
    • Lily Lee

    Correction 22 September 2018 Pages: 1183 - 1183

11. Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

    • John A. Hey
    • Petr Kocis
    • Martin Tolar

    Correction 12 November 2018 Pages: 1185 - 1185